Bioceres Crop Solutions (BIOX) Q2 2025 earnings summary

Executive summary

• Revenues for 2Q25 were $106.7 million, down 24% year-over-year, mainly due to challenging market conditions in Argentina, the company's primary market.

• Net income for 2Q25 was $0.6 million, with Adjusted EBITDA at $15.4 million, both declining from the prior year.

• The company is transitioning to an asset-light, royalty-based business model, exiting direct seed breeding and production to focus on trait development, technology licensing, and partnerships, including new alliances with GDM and Florimond Desprez.

• Milen Marinov was appointed as Chief Commercial Officer to drive commercial performance and growth.

Financial highlights

• Gross profit for 2Q25 was $45.1 million, down 12% year-over-year, but gross margin improved to 42% from 37% due to a favorable product mix.

• Adjusted EBITDA was $15.4 million, down from $24.1 million in the prior year, mainly due to lower crop protection gross profit and weaker JV performance.

• Net debt at quarter-end was $238.3 million, up from $181.6 million a year earlier, with a leverage ratio of 3.3x.

• Inventory levels were 18% lower year-over-year due to tighter management.

• Cash and cash equivalents stood at $29.2 million at quarter-end.

Outlook and guidance

• Management remains optimistic about mid- and long-term prospects, focusing on capital allocation, cost efficiencies, and transitioning to an asset-light model.

• Near-term focus is on enhancing profitability, cash flows, and reducing accounts receivable.

• Additional cost reductions and OpEx savings are expected before year-end, contributing to EBITDA stabilization.